{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:08:08Z","timestamp":1778638088379,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Important and Weak Subject Construction Project of Shanghai Health and Family Planning System","award":["2016ZB020"],"award-info":[{"award-number":["2016ZB020"]}]},{"name":"Clinical Research Innovation Plan of Shanghai General Hospital","award":["CTCCR-2016B01"],"award-info":[{"award-number":["CTCCR-2016B01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4388-2","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T10:04:13Z","timestamp":1567764253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial)"],"prefix":"10.1186","volume":"19","author":[{"given":"Zhigang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruilan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"issue":"1","key":"4388_CR1","first-page":"18","volume":"40","author":"I Azkarate","year":"2016","unstructured":"Azkarate I, Choperena G, Salas E, Sebastian R, Lara G, Elosegui I, et al. Epidemiology and prognostic factors in severe sepsis\/septic shock. Evolution over six years. Med Int. 2016;40(1):18\u201325.","journal-title":"Med Int"},{"issue":"5","key":"4388_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s00134-017-4750-z","volume":"43","author":"MJ Schultz","year":"2017","unstructured":"Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Med. 2017;43(5):612\u201324.","journal-title":"Intensive Care Med"},{"issue":"9","key":"4388_CR3","doi-asserted-by":"publisher","first-page":"e107181","DOI":"10.1371\/journal.pone.0107181","volume":"9","author":"J Zhou","year":"2014","unstructured":"Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, et al. Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland China. PLoS One. 2014;9(9):e107181.","journal-title":"PLoS One"},{"issue":"5","key":"4388_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMp1707170","volume":"377","author":"K Reinhart","year":"2017","unstructured":"Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing Sepsis as a Global Health priority - a WHO resolution. N Engl J Med. 2017;377(5):414\u20137.","journal-title":"N Engl J Med"},{"issue":"3","key":"4388_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/SHK.0000000000000868","volume":"48","author":"B Cheng","year":"2017","unstructured":"Cheng B, Li Z, Wang J, Xie G, Liu X, Xu Z, et al. Comparison of the performance between Sepsis-1 and Sepsis-3 in ICUs in China: a retrospective multicenter study. Shock. 2017;48(3):301\u20136.","journal-title":"Shock."},{"issue":"3","key":"4388_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"issue":"15","key":"4388_CR7","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa1305727","volume":"370","author":"P Caironi","year":"2014","unstructured":"Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370(15):1412\u201321.","journal-title":"N Engl J Med"},{"issue":"17","key":"4388_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2016.14799","volume":"316","author":"D Keh","year":"2016","unstructured":"Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al. Effect of hydrocortisone on development of shock among patients with severe Sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;316(17):1775\u201385.","journal-title":"JAMA."},{"issue":"5","key":"4388_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/thoraxjnl-2015-208017","volume":"71","author":"VD Dinglas","year":"2016","unstructured":"Dinglas VD, Hopkins RO, Wozniak AW, Hough CL, Morris PE, Jackson JC, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax. 2016;71(5):401\u201310.","journal-title":"Thorax."},{"issue":"13","key":"4388_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/jama.2017.2088","volume":"317","author":"Y Kawazoe","year":"2017","unstructured":"Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, et al. Effect of Dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with Sepsis: a randomized clinical trial. JAMA. 2017;317(13):1321\u20138.","journal-title":"JAMA."},{"issue":"6","key":"4388_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1177\/0310057X0703500604","volume":"35","author":"B Sharma","year":"2007","unstructured":"Sharma B, Sharma M, Majumder M, Steier W, Sangal A, Kalawar M. Thrombocytopenia in septic shock patients--a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35(6):874\u201380.","journal-title":"Anaesth Intensive Care"},{"issue":"4","key":"4388_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00134-015-4012-x","volume":"42","author":"L Pigozzi","year":"2016","unstructured":"Pigozzi L, Aron JP, Ball J, Cecconi M. Understanding platelet dysfunction in sepsis. Intensive Care Med. 2016;42(4):583\u20136.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4388_CR13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.21536","volume":"85","author":"TA Rousan","year":"2010","unstructured":"Rousan TA, Aldoss IT, Cowley BD Jr, Curtis BR, Bougie DW, Aster RH, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol. 2010;85(1):71\u20134.","journal-title":"Am J Hematol"},{"issue":"18","key":"4388_CR14","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","volume":"123","author":"CN Morrell","year":"2014","unstructured":"Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123(18):2759\u201367.","journal-title":"Blood."},{"issue":"Suppl 1","key":"4388_CR15","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1016\/j.thromres.2018.01.049","volume":"164","author":"J Cedervall","year":"2018","unstructured":"Cedervall J, Hamidi A, Olsson AK. Platelets, NETs and cancer. Thromb Res. 2018;164(Suppl 1):S148\u2013S52.","journal-title":"Thromb Res"},{"issue":"6214","key":"4388_CR16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1126\/science.1256478","volume":"346","author":"V Sreeramkumar","year":"2014","unstructured":"Sreeramkumar V, Adrover JM, Ballesteros I, Cuartero MI, Rossaint J, Bilbao I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science. 2014;346(6214):1234\u20138.","journal-title":"Science."},{"issue":"1","key":"4388_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2052-0492-1-9","volume":"1","author":"C Venkata","year":"2013","unstructured":"Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1(1):9.","journal-title":"J Intensive Care"},{"issue":"4","key":"4388_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/CCM.0000000000003644","volume":"47","author":"CE Menard","year":"2019","unstructured":"Menard CE, Kumar A, Houston DS, Turgeon AF, Rimmer E, Houston BL, et al. Evolution and impact of thrombocytopenia in septic shock: a retrospective cohort study. Crit Care Med. 2019;47(4):558\u201365.","journal-title":"Crit Care Med"},{"issue":"4","key":"4388_CR19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/CCM.0000000000001520","volume":"44","author":"N Thiery-Antier","year":"2016","unstructured":"Thiery-Antier N, Binquet C, Vinault S, Meziani F, Boisrame-Helms J, Quenot JP, et al. Is thrombocytopenia an early prognostic marker in septic shock? Crit Care Med. 2016;44(4):764\u201372.","journal-title":"Crit Care Med"},{"issue":"24","key":"4388_CR20","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2015-11-680744","volume":"127","author":"TA Claushuis","year":"2016","unstructured":"Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood. 2016;127(24):3062\u201372.","journal-title":"Blood."},{"issue":"4","key":"4388_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jinf.2018.12.002","volume":"78","author":"Y Xie","year":"2019","unstructured":"Xie Y, Tian R, Xie H, Jin W, Du J, Huang P, et al. The clinical significance of thrombocytopenia complicating sepsis: a meta-analysis. J Infect. 2019;78(4):323\u201337.","journal-title":"J Infect"},{"issue":"6","key":"4388_CR22","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1378\/chest.06-2233","volume":"131","author":"D Moreau","year":"2007","unstructured":"Moreau D, Timsit JF, Vesin A, Garrouste-Orgeas M, de Lassence A, Zahar JR, et al. Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest. 2007;131(6):1735\u201341.","journal-title":"Chest."},{"issue":"1","key":"4388_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1182\/asheducation-2007.1.172","volume":"2007","author":"S. J. Slichter","year":"2007","unstructured":"Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program. 2007:172\u20138. https:\/\/doi.org\/10.1182\/asheducation-2007.1.172 .","journal-title":"Hematology"},{"issue":"10","key":"4388_CR24","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","volume":"100","author":"DJ Kuter","year":"2002","unstructured":"Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100(10):3457\u201369.","journal-title":"Blood."},{"issue":"1","key":"4388_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/asheducation-2009.1.147","volume":"2009","author":"K. Kaushansky","year":"2009","unstructured":"Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program. 2009:147\u201352. https:\/\/doi.org\/10.1182\/asheducation-2009.1.147 .","journal-title":"Hematology"},{"issue":"22","key":"4388_CR26","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","volume":"116","author":"W Bao","year":"2010","unstructured":"Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639\u201345.","journal-title":"Blood."},{"issue":"2","key":"4388_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","volume":"96","author":"S Wang","year":"2012","unstructured":"Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222\u20138.","journal-title":"Int J Hematol"},{"issue":"10","key":"4388_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2014-06-581868","volume":"125","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu M, Qin P, Zhang HY, Yuan CL, Zhao HG, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541\u20137.","journal-title":"Blood."},{"issue":"4","key":"4388_CR29","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282\u201394.","journal-title":"Oncology (Williston Park)"},{"issue":"9","key":"4388_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1182\/blood-2017-01-761262","volume":"130","author":"Z Kong","year":"2017","unstructured":"Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097\u2013103.","journal-title":"Blood."},{"key":"4388_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcrc.2015.11.010","volume":"32","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Chondropoulos S, Frantzeskaki F, Stamouli M, Gkirkas K, Bartzeliotou A, et al. Thrombocytopenia in critically ill patients with severe sepsis\/septic shock: prognostic value and association with a distinct serum cytokine profile. J Crit Care. 2016;32:9\u201315.","journal-title":"J Crit Care"},{"issue":"5","key":"4388_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1055\/s-0037-1616068","volume":"86","author":"FB Taylor Jr","year":"2001","unstructured":"Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific subcommittee on disseminated intravascular coagulation of the international society on T, et al. towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327\u201330.","journal-title":"Thromb Haemost"},{"issue":"9","key":"4388_CR33","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/sj.leu.2401514","volume":"13","author":"US Schwertschlag","year":"1999","unstructured":"Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia. 1999;13(9):1307\u201315.","journal-title":"Leukemia."},{"issue":"9354","key":"4388_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(03)12322-7","volume":"361","author":"M Ellis","year":"2003","unstructured":"Ellis M, Zwaan F, Hedstrom U, Poynton C, Kristensen J, Jumaa P, et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361(9354):275\u201380.","journal-title":"Lancet."},{"issue":"2","key":"4388_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cyto.2015.08.001","volume":"76","author":"B Wan","year":"2015","unstructured":"Wan B, Zhang H, Fu H, Chen Y, Yang L, Yin J, et al. Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study. Cytokine. 2015;76(2):138\u201343.","journal-title":"Cytokine."},{"issue":"10039","key":"4388_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","volume":"388","author":"MD Tarantino","year":"2016","unstructured":"Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45\u201354.","journal-title":"Lancet."},{"key":"4388_CR37","first-page":"CD012035","volume":"11","author":"X Zhang","year":"2017","unstructured":"Zhang X, Chuai Y, Nie W, Wang A, Dai G. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev. 2017;11:CD012035.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4388_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","volume":"104","author":"W Ghanima","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112\u201323.","journal-title":"Haematologica."},{"issue":"1","key":"4388_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1076029613487429","volume":"21","author":"J Lin","year":"2015","unstructured":"Lin J, Zhu H, Li S, Fan H, Lu X. Recombinant human thrombopoietin alleviates infection-associated thrombocytopenia: a retrospective study in senile patients. Clin Appl Thromb Hemost. 2015;21(1):19\u201324.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"4388_CR40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jcrc.2013.11.023","volume":"29","author":"Q Wu","year":"2014","unstructured":"Wu Q, Ren J, Wu X, Wang G, Gu G, Liu S, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study. J Crit Care. 2014;29(3):362\u20136.","journal-title":"J Crit Care"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4388-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4388-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4388-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T01:30:26Z","timestamp":1721698226000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4388-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4388-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RL. W declares that RhTPO in this study will be sponsored by Shenyang Sunshine Pharmaceutical Co., Ltd. And Shenyang Sunshine Pharmaceutical Co., Ltd. has no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"780"}}